We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Test Tube Method Screens for Variant Hemoglobin

By LabMedica International staff writers
Posted on 14 Dec 2011
A ready-to-use test tube method for Hemoglobin E (HbE) has been described that can be employed as a screening test kit. More...


The novel test-tube method for HbE screening uses diethyl aminoethyl (DEAE)-cellulose resin and it is based on the principle of anion-exchange liquid chromatography.

Scientists at Chiang Mai University (Thailand) used the principle where DEAE-cellulose resin was used as the stationary phase, and glycine buffer with sodium chloride as the mobile phase. However, the method was set to be completed inside the tube instead of in an open-ended column. Equilibrated DEAE-cellulose resin is added to polystyrene tubes, followed by the addition of 2 mL eluting buffer. The tubes are capped and stored at 4 °C.

For HbE screen, packed red blood cells are mixed with a hemolysis reagent to obtain the hemolysate. An aliquot of hemolysate is added to the tube containing DEAE-cellulose resin suspension in eluting buffer, mixed vigorously and centrifuged. The color of the supernatant was then visualized after centrifugation. If the color of the supernatant was red, the result was positive, whereas a colorless or markedly pale red supernatant was negative. A positive result indicated the presence of HbE, while a negative result suggested the absence of HbE in the blood samples.

One hundred and thirteen blood samples were screened for HbE by the test tube method and by standard cellulose acetate electrophoresis (CAE). Seven of 113 samples were found to be positive for HbE by the tube method, in complete agreement with the findings from the CAE. The test-tube method is cheap and simple with no requirement of sophisticated equipment. The reagent could be stored at 4 °C for up to five months. Hemolysate samples aged up to five months were still suitable for this test.

HbE is a β-structural variant common worldwide. This Hb disorder can form a compound heterozygous state with the β-thalassemia gene, leading to life-threatening hereditary hemolytic anemia, HbE/β-thalassemia. The authors concluded that the novel test-tube method using the DEAE-cellulose resin (Sigma-Aldrich, Saint Louis, MO, USA) could be an alternative method of mass population screening for HbE, particularly in small health care facilities. The study was published online on August 23, 2011, in the International Journal of Laboratory Hematology.

Related Links:
Chiang Mai University
Sigma-Aldrich


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Automated Immunoassay Analyzer
SuperFlex™
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.